Departments of Gastrointestinal Medical Oncology.
Endoscopic Room.
J Immunother. 2022;45(9):415-422. doi: 10.1097/CJI.0000000000000438. Epub 2022 Aug 26.
In recent years, a growing number of clinical studies have shown that immune checkpoint inhibitor (ICI) can increase the remission rate and improve the prognosis of patients with esophageal cancer. The Controlling Nutritional Status (CONUT) score is a novel nutritional indicator that can predict the prognosis of certain malignancies. We retrospectively analyzed the clinical data of 69 patients with advanced esophageal cancer treated with ICI and assessed the relationship between clinicopathological factors including CONUT score, systemic immune-inflammatory index (SII), and neutrophil-to-lymphocyte ratio and the prognosis. We found the CONUT score and SII, neutrophil-to-lymphocyte ratio were an independent prognostic factor for overall survival ( P <0.05). Furthermore, among patients treated with ICI, a high CONUT score was associated with a significantly worse progression-free survival (PFS) and overall survival compared with a low CONUT group. In conclusion, the CONUT can be used to predict the efficacy and prognosis of ICI therapy in patients with esophageal cancer. Our studies have shown that the CONUT score can be used as an effective indicator for the prognosis of patients with esophageal cancer receiving ICI.
近年来，越来越多的临床研究表明，免疫检查点抑制剂（ICI）可以提高食管癌患者的缓解率并改善预后。控制营养状况（CONUT）评分是一种新的营养指标，可以预测某些恶性肿瘤的预后。我们回顾性分析了 69 例接受 ICI 治疗的晚期食管癌患者的临床资料，并评估了 CONUT 评分、全身性免疫炎症指数（SII）和中性粒细胞与淋巴细胞比值等临床病理因素与预后的关系。结果发现，CONUT 评分和 SII、中性粒细胞与淋巴细胞比值是总生存期的独立预后因素（P<0.05）。此外，在接受 ICI 治疗的患者中，与低 CONUT 组相比，高 CONUT 评分与无进展生存期（PFS）和总生存期显著更差相关。总之，CONUT 可用于预测食管癌患者接受 ICI 治疗的疗效和预后。我们的研究表明，CONUT 评分可作为预测接受 ICI 治疗的食管癌患者预后的有效指标。
